Leucegene data availability statement

Leucegene data availability statement

The datasets generated by the Leucegene project are only partially accessible to the public due to legal and ethical limitations. We understand the importance of data availability and are actively working to make the findings of our project accessible to the scientific community. Currently, our focus is on writing articles that summarize our discoveries, while simultaneously preparing the data, Research Ethics Board approval, and Institutional Certifications for the release of genomic and clinical data through GEO (Gene Expression Omnibus) and dbGaP (database of Genotypes and Phenotypes).

Ensuring ethical compliance in the release of data requires a significant amount of time and effort including going through dbGaP submission process. Consequently, we regret that we may not be able to address individual data requests in the upcoming months. We appreciate your understanding and patience during this period. We are fully committed to upholding transparency and accessibility, and we look forward to sharing our findings with the scientific community.

Meanwhile to circumvent these limitations, please note that we are open to scientific collaborations. You can contact the Leucegene principal investigators for specific requests related to your project:

Guy.sauvageau@umontreal.ca : surfaceome data, IC50 of selected clinical compounds in chemical screens

Josee.hebert@umontreal.ca: morphology, cytogenetics, validated clinical data prepared by the Quebec leukemia cell bank for the Leucegene project

S.lemieux@umontreal.ca : sequencing data, bioinformatics

Anne.marinier@umontreal.ca : chemistry and molecules

 

 

Leucegene data availability statement

Leucegene data availability statement

The datasets generated by the Leucegene project are only partially accessible to the public due to legal and ethical limitations. We understand the importance of data availability and are actively working to make the findings of our project accessible to the scientific community. Currently, our focus is on writing articles that summarize our discoveries, while simultaneously preparing the data, Research Ethics Board approval and Institutional Certifications for release of genomic and clinical data through GEO (Gene Expression Omnibus) and dbGaP (database of Genotypes and Phenotypes).

Ensuring ethical compliance in the release of data requires a significant amount of time and effort including going through dbGaP submission process. Consequently, we regret that we may not be able to address individual data requests in the upcoming months. We appreciate your understanding and patience during this period. We are fully committed to upholding transparency and accessibility, and we look forward to sharing our findings with the scientific community.

Please note that we are open to scientific collaborations. You can contact the Leucegene principal investigators for specific request related to your project:

Guy.sauvageau@umontreal.ca : surfaceome data, IC50 of selected clinical compounds in chemical screens

Josee.hebert@umontreal.ca: morphology, cytogenetics, validated clinical data prepared by the Quebec leukemia cell bank for the Leucegene project

Sebastien.lemieux@umontreal.ca : sequencing data

 

The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published

Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.